MUC1 recombinant proteins and antibodies

Mucin MUC1 (Mucin1, also known as MAM6 and EMA) is a surface mucin belonging to the mucin family and a type I transmembrane protein. Under normal circumstances, MUC1 is widely distributed on the normal mucosal surfaces of the body, including the apical surface of glandular or luminal epithelial cells of the breast, esophagus, stomach, duodenum, pancreas, uterus, prostate and lung; and is also expressed to a lesser extent in hematopoietic cells. Studies have found that MUC1 is highly expressed in epithelial tumor tissues (such as lung cancer, pancreatic cancer, prostate cancer, epithelial ovarian cancer, breast cancer, etc.), and its expression is related to tumor metastasis and recurrence. Based on the role of MUC1 in tumor occurrence and progression and its expression characteristics in tumor tissues, MUC1 is considered a potential target for the development of solid tumor drugs. At present, many pharmaceutical companies around the world have developed a variety of immunotherapies for the MUC1 target, and the fastest of them is in phase 2 clinical trials. More about the progress of clinical research on MUC1 >>

DIMA BIOTECH now provides a full range of products and services for MUC1 targets. Products include active proteins, reference antibodies, and flow cytometry-validated monoclonal antibodies; services include customized services for antibodies of various genera, antibody humanization, and affinity maturation services. In addition, to accelerate the development of MUC1 biotherapy, DIMA BIOTECH has also prepared a single B cell seed bank for MUC1 targets, and lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have also conducted CAR-T or ADC molecule construction and functional verification for some existing MUC1 lead antibody molecules. Please feel free to inquire for specific data.